Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.

Daniela Egli-SpichtigAhmad Kamal HamidEva Maria Pastor ArroyoMarkus KettelerAndrzej WiecekAlexander R RosenkranzAndreas PaschHorst LorenzBurkhard HellmannMichael KarusRichard AmmerIsabel Rubio-Aliaga Carsten Alexander Wagner

Published in: Clinical kidney journal (2023)

Lowering serum phosphate in ESKF patients may depend highly on iFGF23 which is correlated to cFGF23 levels. Serum phosphate was the most important predictor of plasma FGF23 in this ESKF cohort.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
replacement therapy